去纤苷在中国有吗？

(also called defibrotide sodium) is currently the most effective drug for the treatment of hepatic veno-occlusive disease (HOVD) after hematopoietic stem cell transplantation (HSCT). On March 30, 2016, the U.S. Food and Drug Administration (FDA) approved defibrotide (defibrotide sodium) for the treatment of hepatic veno-occlusive disease (VOD) caused by hematopoietic stem cell transplantation in adults and children with renal and pulmonary dysfunction. Today we will learn more about whether defibrotide is available in China? Defibrotide (also called defibrotide sodium) has not yet been officially launched in China. Patients in need can purchase the version available abroad. According to Medical Companion Travel, the price of defibrotide is about 22,000. Patients can purchase drugs abroad or obtain drugs through domestic professional overseas medical service organizations (such as Medical Companion Travel), and sign a guarantee contract to guarantee 100% authenticity!

Recommended usage of defibrinoside:

The recommended dose for adult and pediatric patients is 6.25 mg/kg given as a 2-hour intravenous infusion every 6 hours. The dose should be based on the patient's baseline weight, which is defined as the patient's weight before the HSCT (hematopoietic stem cell transplant) preparation protocol. Defibrotide was administered for a minimum of 21 days. If signs and symptoms of hepatic veno-occlusive disease have not resolved after 21 days, continue defibrotide until resolution of hepatic veno-occlusive disease or for a maximum of 60 days.

Defibrotide must be diluted prior to infusion. Do not coadminister defibrotide with other intravenous medications at the same time and in the same intravenous line.

A multicenter phase II randomized study divided 150 HVOD patients into two groups, who were treated with defibrinoside 25 mg/kg (group A) and 40 mg/kg (group B) every day, with a median treatment time of 19 (1-82) days.

Results: 141 patients were evaluable for efficacy: 65 patients achieved complete remission (46%), and 62 patients were still alive at 100 days (41%). Although grade 3/4 events in patients in group B included increased bleeding and hypotension, the difference was not statistically significant compared with patients in group A, indicating that the side effects of high-dose defibrotide were smaller and that defibrotide was safe and effective in the treatment of HVOD.

Defibrotide (also called defibrotide sodium) is a polydisperse mixture of single-stranded oligonucleotides that can prevent endothelial cell damage without increasing the risk of systemic bleeding, and protect hepatic sinusoidal endothelial cells without weakening the anti-tumor effect of cytotoxic drugs.

The above is the content of the purchase channels for (also called fiber-free sodium), I hope it can help you!

Recommended related hot articles: /newsDetail/84575.html